# Anakinra vs Prednisone to Treat Gout Flare in Patients With Chronic Kidney Disease Stage 4/5 or Renal Transplantation

Study · id `cardio:ct-nct04844814` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04844814](<https://clinicaltrials.gov/study/NCT04844814>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04844814

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is suspended. It plans to enroll 204 participants.

## Technical summary

Registry record NCT04844814. Randomized; quadruple masking; primary purpose treatment. Start 2022-06-02 (actual); primary completion 2025-02-12 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 204 participants (planned count; ClinicalTrials.gov record NCT04844814, source copy `cardio:ctgov-nct04844814-2026-02-04`, retrieved 2026-10-26)
- Started: 2022-06-02 (actual) (ClinicalTrials.gov record NCT04844814, source copy `cardio:ctgov-nct04844814-2026-02-04`, retrieved 2026-10-26)
- Primary completion: 2025-02-12 (actual) (ClinicalTrials.gov record NCT04844814, source copy `cardio:ctgov-nct04844814-2026-02-04`, retrieved 2026-10-26)
- Completion: 2026-08-31 (anticipated) (ClinicalTrials.gov record NCT04844814, source copy `cardio:ctgov-nct04844814-2026-02-04`, retrieved 2026-10-26)
- Countries: France (ClinicalTrials.gov record NCT04844814, source copy `cardio:ctgov-nct04844814-2026-02-04`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "SUSPENDED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04844814-2026-02-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: Anakinra vs Prednisone to Treat Gout Flare in Patients With Chronic Kidney Disease Stage 4/5 or Renal Transplantation
- Acronym: Ana4CKD
- Condition: Gout
- Condition: Chronic Kidney Disease
- Condition: Renal Transplantation
- Intervention (Drug): Anakinra 100Mg/0.67Ml Inj Syringe
- Intervention (Drug): Prednisone
- Intervention (Drug): Placebo of Prednisone
- Intervention (Drug): Placebo of Anakinra
- Lead sponsor: Assistance Publique - Hôpitaux de Paris
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Assistance Publique - Hôpitaux de Paris (`cardio:org-assistance-publique-hopitaux-de-paris`)

## Provenance

Content hash: c1dca5e86b09b6ae96c22a575ef951c360e6c3454658d70ad10385efa045443c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
